New immunisation reference page: Moderna COVID-19 vaccine
Following the announcement by the Australian Government that 25 million doses (as well as additional variant specific versions) of Moderna's COVID-19 vaccine, Elasomeran, had been secured for the Australian population, this vaccine was last week granted provisional determination by the TGA.
Our new reference page explores the various clinical trials involving Elasomeran, as well as details the immunogenicity, efficacy and safety data available for this vaccine.
अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
MVEC: Moderna COVID-19 vaccine
MVEC eLearning: Vaccines in Pregnancy
MVEC are excited to launch the next of our eLearning packages. Our eLearning packages are designed to allow immunisation providers to consolidate and evaluate their technical skills. Targeted resources are available to assist with our eLearning and a certificate of completion will be made available upon completion of the corresponding eLearning quiz.
Vaccines in Pregnancy has been designed to provide an overview of vaccines that are recommended in pregnancy, vaccines that are contraindicated in pregnancy and the process to follow if a contraindicated vaccine is inadvertently administered during pregnancy.
You can access Vaccines in Pregnancy via our एमवीईसी शिक्षा पोर्टल or via the following link:
MVEC eLearning: Vaccines in Pregnancy
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
The Therapeutic Goods Administration (TGA) has granted provisional determination to Moderna Australia Pty Ltd for their COVID-19 vaccine candidate, Elasomeran. It is being considered for use in those aged 12 years or older for active immunisation to prevent COVID-19 disease. It is an mRNA vaccine requiring two doses, given 28 days apart.
Granting provisional determination means that Moderna Australia Pty Ltd is now eligible to apply for provisional registration. Following the provisional pathway provides a formal and transparent mechanism for speeding up the registration of promising new medicines with preliminary clinical data.
Provisional determination is only granted once the TGA has considered all eligibility criteria, including evidence of a plan to submit comprehensive clinical data.
You can read the press release from the TGA below:
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
For more information on the process of COVID-19 vaccine provisional approval please refer to our reference page:
एमवीईसी: ऑस्ट्रेलिया में सीओवीआईडी-19 वैक्सीन का अनंतिम पंजीकरण
वार्तालाप: ऑस्ट्रेलिया का पहला स्थानीय फाइजर-शैली का COVID वैक्सीन क्या है? और यह हमारी बाहों में कब हो सकता है? एक mRNA विशेषज्ञ बताते हैं
मोनाश विश्वविद्यालय की एक शोध टीम ऑस्ट्रेलिया के पहले एमआरएनए वैक्सीन उम्मीदवार को विकसित करने पर काम कर रही है, जिसके पहले चरण के परीक्षण इस साल अक्टूबर या नवंबर में शुरू होने वाले हैं।
यद्यपि विकास के तहत टीका कोरोनोवायरस के विशिष्ट स्पाइक प्रोटीन के उत्पादन को चिंगारी करने के लिए आरएनए नामक एक आनुवंशिक कोड का उपयोग करके फाइजर और मॉडर्न के टीके के समान सिद्धांतों द्वारा काम करता है, लेकिन प्रमुख उल्लेखनीय अंतर हैं।
सबसे पहले, मोनाश एमआरएनए वैक्सीन कोशिकाओं को स्पाइक प्रोटीन, रिसेप्टर बाइंडिंग डोमेन का एक छोटा सा हिस्सा बनाने के लिए निर्देशित करता है। रिसेप्टर बाइंडिंग डोमेन स्पाइक प्रोटीन की नोक है जो कि वह हिस्सा है जो COVID रोग के नए वेरिएंट बनाने के लिए उत्परिवर्तित हो रहा है। स्पाइक प्रोटीन के इस हिस्से को लक्षित करने से वैरिएंट-विशिष्ट प्रतिक्रियाओं की अनुमति मिलती है, जिसके लिए एक मजबूत नैदानिक आवश्यकता है।
दूसरे, मौजूदा टीकों को वायरस के मूल तनाव पर आधारित किया जाता है जो पहले वुहान में पाया गया था, हालांकि, मोनाश एमआरएनए वैक्सीन को तब से बीटा स्ट्रेन के क्रम में बदल दिया गया है - एक तनाव जो पहली बार दक्षिण अफ्रीका में पाया गया था जिसके लिए मूल से टीके बनाए गए थे। वेरिएंट कम प्रभावी हैं।
यह एमआरएनए टीकों के लचीलेपन पर प्रकाश डालता है, जिसमें दृश्यों को बदला जा सकता है और नए वेरिएंट के लिए अनुकूलित किया जा सकता है जो भविष्य में उभर सकते हैं।
टीके को स्थानीय स्तर पर विकसित करने की योजना पर काम चल रहा है, जो कि mRNA वैक्सीन उत्पादन के लिए ऑस्ट्रेलिया की क्षमता और समग्र रूप से नव विकसित ऑस्ट्रेलियाई आरएनए जैव प्रौद्योगिकी क्षेत्र को विकसित करने की दिशा में एक महत्वपूर्ण कदम है।
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
वार्तालाप: ऑस्ट्रेलिया का पहला स्थानीय फाइजर-शैली का COVID वैक्सीन क्या है? और यह हमारी बाहों में कब हो सकता है? एक mRNA विशेषज्ञ बताते हैं
Healthed Going Viral Podcast featuring A/Prof Nigel Crawford
Associate Professor Nigel Crawford is interviewed by Dr David Lim, GP and Medical Educator on Healthed Australia’s Going Viral podcast. In this podcast, Nigel discusses the clinical features of Thrombosis with thrombocytopenia syndrome (TTS) and provides an approach for diagnosing and managing it.
You can listen to the podcast here:
Healthed Australia: Going Viral Podcast Episode 157: AZ Clots – Are you missing it?
PHN Webinar: Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS)
The PHN will be hosting a webinar for GPs on Wednesday 30 June featuring a panel of expert speakers including MVEC’s A/Prof Nigel Crawford. The topic for the webinar is Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS) and will cover:
- pathogenesis
- latest incidence rates in age groups
- incidence of different TTS clinical types
- presentation and identification
- GP management guidelines.
Further information and details on registration can be found via the link below:
RACGP: Government announces new vaccine counselling MBS item number
Federal Health Minister Greg Hunt has announced the introduction of a newly-created MBS item in response to rising vaccine hesitancy related to widespread reporting the rare condition, thrombosis with thrombocytopenia syndrome, following receipt of the COVID-19 AstraZeneca vaccine. The new Medicare item, known as the Level B equivalent, will provide patients over 50 with a $38.75 rebate when receiving COVID vaccine counselling from their GP.
The introduction of this scheme will allow more time for GPs to address patient concerns and provide support in making informed decisions seen as crucial to boosting vaccination rates.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
RACGP: Government announces new vaccine counselling MBS item number
ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021
ATAGI has revised the recommendations for COVID-19 vaccination within Australia.
Due to a higher risk and severity of thrombosis with thrombycytopenia syndrome (TTS) related to the use of COVID-19 AstraZeneca, Comirnaty™ is now the preferred COVID-19 vaccine for individuals aged 16-59 years. Due to the risk of severe outcomes related to COVID-19 disease for individuals aged 60 years and over, the benefits of vaccination in preventing disease outweighs the risk of developing TTS.
Individuals aged less than 60 years who have received their first dose of COVID-19 AstraZeneca without any serious adverse events (eg. anaphylaxis or TTS) should continue to receive their second dose.
अधिक जानकारी के लिए कृपया नीचे दिए गए लिंक को देखें:
ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021
New immunisation reference page: COVID-19 mixed vaccine schedules
With the emergence of variant COVID-19 strains, global vaccine supply issues, and the need to rapidly immunise the population, a number of clinical trials are investigating the option of “mixed schedules”. Mixed schedules have been used previously in other vaccination strategies and involve the administration of different vaccine brands to complete a vaccine course.
Our new reference page explores the clinical trials underway which aim to determine the safety of mixed scheduling, the immunogenicity, as well as the recommendations for intervals between doses.
Due to a lack of available data, mixed vaccine schedules are not currently approved in Australia however are in use in Canada and across Europe.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
MVEC: COVID-19 mixed vaccine schedules
The New York Times: A Multibillion-Dollar Plan to End Polio, and Soon
The Global Polio Eradication Initiative has announced a $5.1 billion plan to eradicate polio globally by 2026. In August 2021, African countries were declared free of wild polio, leaving Afghanistan and Pakistan as the only remaining countries with endemic disease. Due to inadequate funding and a lack of political commitment, there has previously been limited success in trying to achieve a polio-free world. The coronavirus pandemic has added further challenges, bringing some polio vaccination programs to a halt.
The new initiative is set to focus on two key goals: integrating polio vaccination programs with other health care initiatives and focusing on areas with chronically low immunisation rates. The plan also ensures vaccine supply and outlines a communication strategy to increase vaccine acceptance. In addition to this, a new oral vaccine has been introduced and is thought to minimise the risk of vaccine-induced polio.
A key focus of the polio eradication program will be on immunising hard-to-reach communities, and training older female health workers, who are more successful in persuading caregivers to vaccinate their children. In order to reinstate polio eradication as a priority, even with competing health challenges in these cash poor countries, experts believe that programs designed to crush polio can also be used to help manage COVID-19 and other diseases.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
The New York Times: A Multibillion-Dollar Plan to End Polio, and Soon